JP Morgan Maintains Overweight on Syndax Pharmaceuticals, Raises Price Target to $38
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Anupam Rama maintains an Overweight rating on Syndax Pharmaceuticals (NASDAQ:SNDX) and raises the price target from $36 to $38.
October 17, 2023 | 3:34 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
JP Morgan maintains an Overweight rating on Syndax Pharmaceuticals and raises the price target from $36 to $38, indicating a positive outlook for the company.
The raised price target by JP Morgan indicates a positive outlook for Syndax Pharmaceuticals. This could lead to increased investor confidence and potentially a rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100